Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapFalling Star
    All News

    Brief: Genmab Says Investigational Epcoritamab Monotherapy Achieves High Overall And Complete Response Rates In Clinical Trial

    Picture of Genmab A/S logoGenmab A/S
    08/12/2024 16:01
    Dec 8 (Reuters) - Genmab A/S  GMAB.CO :
    * INVESTIGATIONAL EPCORITAMAB (DUOBODY® CD3XCD20)
MONOTHERAPY
ACHIEVES HIGH OVERALL AND COMPLETE RESPONSE RATES IN CLINICAL
TRIAL OF PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) IN PRELIMINARY ANALYSIS

Source text:  ID:nBw69mdYpa 
Further company coverage:  GMAB.CO 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news